Indian translational research institute specializing in influenza vaccine development, immune profiling, and clinical validation for EU infectious disease consortia.
THSTI is an Indian research institute focused on translational biomedical research, bridging the gap between laboratory discovery and clinical application in infectious diseases. Their H2020 involvement centers on influenza vaccine development — from preclinical validation of next-generation vaccine candidates through to human clinical trials and controlled human infection models. They also contributed to the European SARS-CoV-2 pandemic response through population-based cohort studies and federated data analysis. As an Indian partner in EU consortia, they bring clinical trial infrastructure, immune profiling capabilities, and access to large patient populations in a high-burden disease setting.
Central to INDIGO, ENDFLU, and INCENTIVE — covering recombinant HA constructs, MVA-based constructs, microneedle patches, and adjuvant development across the full preclinical-to-clinical pipeline.
INCENTIVE and INDIGO involve immune profiling, immune monitoring, and human challenge studies to evaluate vaccine responsiveness.
INDIGO specifically works on needle-free intradermal patches and microneedle patch technology for affordable vaccine delivery.
ORCHESTRA involved population-based SARS-CoV-2 studies, federated-learning approaches, and preparedness research across fragile populations.
INCENTIVE explicitly lists technology transfer, and the overall portfolio shows a consistent trajectory from preclinical development through Phase 1 clinical trials.
All four projects started in 2020, so the timeline is compressed rather than showing a multi-year shift. However, the keyword progression reveals a clear pipeline maturation: early keywords focus on laboratory constructs (recombinant HA, HA deletion mutants, MVA-based constructs, adjuvants), while later keywords shift toward clinical and population-level work (human trials, human challenge, immune monitoring, health economics, federated-learning). This suggests THSTI moved from contributing preclinical vaccine science toward playing a role in clinical validation and real-world pandemic response.
THSTI is moving from bench-level vaccine science toward clinical validation and population health data integration, positioning them as a translational partner for infectious disease programs that need clinical trial sites and real-world evidence.
THSTI never coordinates H2020 projects — they join as a participant or international partner, which is typical for non-EU institutions contributing specialized regional capabilities. With 75 unique consortium partners across 19 countries from just 4 projects, they operate in very large international consortia (averaging ~19 partners per project). This makes them a well-connected but non-leading contributor, valued for what they bring to the table rather than for project management.
Despite only 4 projects, THSTI has collaborated with 75 unique partners across 19 countries, reflecting participation in large multi-country vaccine and pandemic consortia. Their network spans Europe broadly, with India as their home base providing access to South Asian clinical populations.
THSTI is one of India's premier translational health institutes, and their H2020 participation specifically fills the gap that European vaccine consortia need: access to clinical trial infrastructure and large patient populations in a high-burden disease setting. For consortium builders, they offer a credible Indian partner with experience in three simultaneous EU influenza vaccine programs — a concentration of flu vaccine expertise that few non-EU institutions can match. Their involvement in ORCHESTRA also signals adaptability, pivoting to pandemic response when needed.
